KEGG   DRUG: Elexacaftor, ivacaftor and tezacaftor
Entry
D11700            Mixture   Drug                                   

Name
Elexacaftor, ivacaftor and tezacaftor;
Trikafta (TN)
Product
Component
Elexacaftor [DR:D11507], Ivacaftor [DR:D09916], Tezacaftor [DR:D11041]
Remark
Product: D11700<US>
Efficacy
Cystic fibrosis treatment
  Disease
Cystic fibrosis (CFTR F508del mutation) [DS:H00218]
Target
CFTR* [HSA_VAR:1080v1] [HSA:1080] [KO:K05031]
  Pathway
hsa02010  ABC transporters
hsa04971  Gastric acid secretion
hsa04972  Pancreatic secretion
hsa04976  Bile secretion
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]
Interaction
Brite
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Cystic Fibrosis Agents
   Conductance Regulator Potentiator
    Elexacaftor/ Tezacaftor/ Ivacaftor
     D11700  Elexacaftor, ivacaftor and tezacaftor
Target-based classification of drugs [BR:br08310]
 Transporters
  ABC transporters
   ABCC subfamily
    CFTR* [HSA_VAR:1080v1]
     D11700  Elexacaftor, ivacaftor and tezacaftor <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11700
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11700
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D11700
Pharmacogenomic biomarkers [br08341.html]
 Germline mutations in genetic disorder treatments
  D11700
Other DBs
PubChem: 405226566
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system